AR095437A1 - Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso - Google Patents

Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso

Info

Publication number
AR095437A1
AR095437A1 ARP140100983A ARP140100983A AR095437A1 AR 095437 A1 AR095437 A1 AR 095437A1 AR P140100983 A ARP140100983 A AR P140100983A AR P140100983 A ARP140100983 A AR P140100983A AR 095437 A1 AR095437 A1 AR 095437A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
pdgf
vegf
methods
portions
Prior art date
Application number
ARP140100983A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR095437A1 publication Critical patent/AR095437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente proporciona proteínas de fusión que comprenden porciones de unión PDGF (factor de crecimiento derivado de plaquetas) y VEGF (factor de crecimiento endotelial vascular), y partículas virales recombinantes que codifican las proteínas de fusión. Además, se proporcionan composiciones que comprenden las proteínas de fusión y las partículas virales, así como también métodos para el uso de las mismas. Célula; vector; kit.
ARP140100983A 2013-03-13 2014-03-13 Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso AR095437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361780914P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
AR095437A1 true AR095437A1 (es) 2015-10-14

Family

ID=50680144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100983A AR095437A1 (es) 2013-03-13 2014-03-13 Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso

Country Status (27)

Country Link
US (4) US9637534B2 (es)
EP (1) EP2968461B1 (es)
JP (2) JP6561042B2 (es)
KR (1) KR102228921B1 (es)
CN (1) CN105188733B (es)
AR (1) AR095437A1 (es)
AU (2) AU2014243712B2 (es)
BR (1) BR112015022208A8 (es)
CA (1) CA2904623A1 (es)
DK (1) DK2968461T3 (es)
ES (1) ES2933558T3 (es)
FI (1) FI2968461T3 (es)
HK (1) HK1220618A1 (es)
HR (1) HRP20221447T1 (es)
HU (1) HUE060464T2 (es)
IL (2) IL240950B (es)
LT (1) LT2968461T (es)
MX (1) MX363533B (es)
PL (1) PL2968461T3 (es)
PT (1) PT2968461T (es)
RS (1) RS63820B1 (es)
RU (1) RU2692652C2 (es)
SG (3) SG10201912956YA (es)
SI (1) SI2968461T1 (es)
TW (1) TWI631133B (es)
UY (1) UY35407A (es)
WO (1) WO2014160507A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
HUE060464T2 (hu) 2013-03-13 2023-03-28 Genzyme Corp PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására
JP2016522249A (ja) * 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
EP3760639A1 (en) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Zwitterionic polymer conjugates
KR101844596B1 (ko) 2014-03-18 2018-04-05 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
CA2953698A1 (en) * 2014-06-28 2015-12-30 Kodiak Sciences Inc. Dual pdgf/vegf antagonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
EP3268386B1 (en) * 2015-03-11 2021-03-31 Allgenesis Biotherapeutics Inc. Fusion protein comprising a ligand binding domain of vegf and pdgf.
CA2987884C (en) * 2015-06-28 2023-01-03 Allgenesis Biotherapeutics Inc. Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. VEGF BINDING METHODS AND COMPOSITIONS
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
KR102477536B1 (ko) 2016-03-30 2022-12-13 에이비 바이오사이언시즈 인코포레이티드 재조합 정맥내 면역글로불린(rIVIG) 조성물 및 이의 제조 및 사용 방법
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP6849390B2 (ja) * 2016-10-28 2021-03-24 花王株式会社 関節のこわばり改善剤
WO2019083171A2 (ko) * 2017-10-26 2019-05-02 주식회사 큐로진생명과학 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
WO2019096226A1 (en) * 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
EA202091786A1 (ru) * 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
KR102505262B1 (ko) * 2019-12-04 2023-03-03 (주) 씨드모젠 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 당뇨망막병증 치료용 조성물
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN113105558A (zh) * 2021-04-01 2021-07-13 芜湖英特菲尔生物制品产业研究院有限公司 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法
IL309392A (en) * 2021-06-18 2024-02-01 Ikarovec Ltd Retinal disorders
WO2023199951A1 (ja) * 2022-04-13 2023-10-19 株式会社セルージョン 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4952515A (en) 1987-05-22 1990-08-28 Polymer Technology International Corp. Method of detection using a test strip having a non particulate dialyzed polymer layer
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
ES2147729T3 (es) 1991-01-31 2000-10-01 Cor Therapeutics Inc Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1916258T3 (da) 1999-08-09 2014-07-28 Genzyme Corp Forøgelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE60117550T2 (de) 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003077796A2 (en) 2002-03-15 2003-09-25 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
BRPI0515264B1 (pt) 2004-09-13 2018-12-18 Genzyme Corp proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DE102005020510A1 (de) 2005-04-29 2006-11-09 Basf Ag Verbundelement, insbesondere Fensterscheibe
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
BRPI0908496A2 (pt) * 2008-02-20 2019-01-15 Genzyme Corp inibição de angiogênese
SI2274008T1 (sl) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
WO2012075184A2 (en) * 2010-12-02 2012-06-07 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
HUE060464T2 (hu) 2013-03-13 2023-03-28 Genzyme Corp PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására

Also Published As

Publication number Publication date
MX363533B (es) 2019-03-27
AU2014243712A1 (en) 2015-10-15
AU2014243712B2 (en) 2018-09-13
JP2019123711A (ja) 2019-07-25
SG10201707501TA (en) 2017-10-30
IL240950B (en) 2019-06-30
IL240950A0 (en) 2015-11-30
KR102228921B1 (ko) 2021-03-16
JP2016513669A (ja) 2016-05-16
HUE060464T2 (hu) 2023-03-28
FI2968461T3 (fi) 2023-01-13
KR20150126923A (ko) 2015-11-13
US20220064262A1 (en) 2022-03-03
EP2968461B1 (en) 2022-09-21
SG10201912956YA (en) 2020-02-27
WO2014160507A1 (en) 2014-10-02
CN105188733B (zh) 2020-05-08
US20140315804A1 (en) 2014-10-23
AU2018278902A1 (en) 2019-01-03
JP6561042B2 (ja) 2019-08-14
BR112015022208A2 (pt) 2017-10-10
LT2968461T (lt) 2022-12-27
US20190345223A1 (en) 2019-11-14
SG11201506802SA (en) 2015-09-29
DK2968461T3 (da) 2022-12-19
TW201506038A (zh) 2015-02-16
BR112015022208A8 (pt) 2018-01-23
EP2968461A1 (en) 2016-01-20
RU2015142999A (ru) 2017-04-17
CN105188733A (zh) 2015-12-23
CA2904623A1 (en) 2014-10-02
US11084864B2 (en) 2021-08-10
UY35407A (es) 2014-10-31
HRP20221447T1 (hr) 2023-01-20
SI2968461T1 (sl) 2023-01-31
IL266715A (en) 2019-07-31
ES2933558T3 (es) 2023-02-10
RU2692652C2 (ru) 2019-06-25
MX2015011951A (es) 2016-04-07
PT2968461T (pt) 2022-12-26
US20170342127A1 (en) 2017-11-30
TWI631133B (zh) 2018-08-01
PL2968461T3 (pl) 2023-01-30
US9637534B2 (en) 2017-05-02
HK1220618A1 (zh) 2017-05-12
US10183983B2 (en) 2019-01-22
RS63820B1 (sr) 2023-01-31

Similar Documents

Publication Publication Date Title
AR095437A1 (es) Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
CL2017002454A1 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
CL2015002669A1 (es) Polipeptidos que contienen región fc aglicosilada
EA202090216A2 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
AR091024A1 (es) Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
EA201391523A1 (ru) Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
MX2016002208A (es) Polipeptidos de union a c5.
WO2015041809A3 (en) Small molecule cellular reprogramming to generate neuronal cells
AR095268A1 (es) ANTICUERPOS HUMANOS QUE SE UNEN AL FACTOR a DE LA NECROSIS (TNF-a) HUMANO Y MÉTODOS PARA PREPARARLOS
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
BR112016019868A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações, e seu uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure